IDEAS home Printed from https://ideas.repec.org/r/wly/hlthec/v12y2003i5p421-427.html
   My bibliography  Save this item

Stratified cost‐effectiveness analysis: a framework for establishing efficient limited use criteria

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Noemi Kreif & Richard Grieve & Rosalba Radice & Zia Sadique & Roland Ramsahai & Jasjeet S. Sekhon, 2012. "Methods for Estimating Subgroup Effects in Cost-Effectiveness Analyses That Use Observational Data," Medical Decision Making, , vol. 32(6), pages 750-763, November.
  2. Domenico Depalo, 2020. "Explaining the causal effect of adherence to medication on cholesterol through the marginal patient," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 110-126, October.
  3. Manuel Antonio Espinoza & Andrea Manca & Karl Claxton & Mark Sculpher, 2018. "Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 28-40, February.
  4. Elamin Elbasha & Jagpreet Chhatwal, 2015. "Characterizing Heterogeneity Bias in Cohort-Based Models," PharmacoEconomics, Springer, vol. 33(8), pages 857-865, August.
  5. Gravelle, Hugh & Siciliani, Luigi, 2008. "Ramsey waits: Allocating public health service resources when there is rationing by waiting," Journal of Health Economics, Elsevier, vol. 27(5), pages 1143-1154, September.
  6. Olivier Ethgen & Baudouin Standaert, 2012. "Population–versus Cohort–Based Modelling Approaches," PharmacoEconomics, Springer, vol. 30(3), pages 171-181, March.
  7. Deon Lingervelder & Hendrik Koffijberg & Ron Kusters & Maarten J. IJzerman, 2021. "Health Economic Evidence of Point-of-Care Testing: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 5(2), pages 157-173, June.
  8. Gregory J. Critchley & Gregory S. Zaric, 2019. "The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare," Health Economics, John Wiley & Sons, Ltd., vol. 28(8), pages 1035-1051, August.
  9. David Glynn & John Giardina & Julia Hatamyar & Ankur Pandya & Marta Soares & Noemi Kreif, 2024. "Integrating decision modeling and machine learning to inform treatment stratification," Health Economics, John Wiley & Sons, Ltd., vol. 33(8), pages 1772-1792, August.
  10. Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294, November.
  11. George Laking & Joanne Lord & Alastair Fischer, 2006. "The economics of diagnosis," Health Economics, John Wiley & Sons, Ltd., vol. 15(10), pages 1109-1120, October.
  12. David D. Kim & Anirban Basu, 2017. "New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives," Medical Decision Making, , vol. 37(8), pages 930-941, November.
  13. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
  14. Rosella Levaggi & Paolo Pertile, 2020. "Which valued‐based price when patients are heterogeneous?," Health Economics, John Wiley & Sons, Ltd., vol. 29(8), pages 923-935, August.
  15. Joanne Lord & George Laking & Alastair Fischer, 2006. "Non‐linearity in the cost‐effectiveness frontier," Health Economics, John Wiley & Sons, Ltd., vol. 15(6), pages 565-577, June.
  16. Laura Levaggi & Rosella Levaggi, 2016. "Welfare analysis of rationing in health care provision," Working papers 39, Società Italiana di Economia Pubblica.
  17. Pepijn Vemer & Lucas M. A. Goossens & Maureen P. M. H. Rutten-van Mölken, 2014. "Not Simply More of the Same," Medical Decision Making, , vol. 34(8), pages 1048-1058, November.
  18. Carl Bonander & Mikael Svensson, 2021. "Using causal forests to assess heterogeneity in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 30(8), pages 1818-1832, August.
  19. Helen O’Donnell & Laura McCullagh & Michael Barry & Cathal Walsh, 2020. "The Interaction between Price Negotiations and Heterogeneity: Implications for Economic Evaluations," Medical Decision Making, , vol. 40(2), pages 144-155, February.
  20. Rosella Levaggi & Paolo Pertile, 2016. "Pricing policies when patients are heterogeneous: a welfare analysis," Working Papers 17/2016, University of Verona, Department of Economics.
  21. Jacco Thijssen, 2007. "Ramsey Waits: A Computational Study on General Equilibrium Pricing of Derivative Securities," Discussion Papers 07/16, Department of Economics, University of York.
  22. Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore, 2013. "Acknowledging Patient Heterogeneity in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(2), pages 111-123, February.
  23. Hui Zhang & Gregory Zaric, 2015. "Using price–volume agreements to manage pharmaceutical leakage and off-label promotion," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(7), pages 747-761, September.
  24. Doug Coyle, 2020. "Who would benefit from average value‐based pricing?," Health Economics, John Wiley & Sons, Ltd., vol. 29(8), pages 936-937, August.
  25. Anna Heath & Petros Pechlivanoglou, 2022. "Prioritizing Research in an Era of Personalized Medicine: The Potential Value of Unexplained Heterogeneity," Medical Decision Making, , vol. 42(5), pages 649-660, July.
  26. Dukhanin, Vadim & Searle, Alexandra & Zwerling, Alice & Dowdy, David W. & Taylor, Holly A. & Merritt, Maria W., 2018. "Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review," Social Science & Medicine, Elsevier, vol. 198(C), pages 27-35.
  27. Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294.
  28. Richard M. Nixon & Simon G. Thompson, 2005. "Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 14(12), pages 1217-1229, December.
  29. Laura Levaggi & Rosella Levaggi, 2017. "Rationing in health care provision: a welfare approach," International Journal of Health Economics and Management, Springer, vol. 17(2), pages 235-249, June.
  30. Daniel Gallacher & Nigel Stallard & Peter Kimani & Elvan Gökalp & Juergen Branke, 2022. "Development of a model to demonstrate the impact of National Institute of Health and Care Excellence cost‐effectiveness assessment on health utility for targeted medicines," Health Economics, John Wiley & Sons, Ltd., vol. 31(2), pages 417-430, February.
  31. Gemma E. Shields & Paul Clarkson & Ash Bullement & Warren Stevens & Mark Wilberforce & Tracey Farragher & Arpana Verma & Linda M. Davies, 2024. "Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature," PharmacoEconomics, Springer, vol. 42(7), pages 737-749, July.
  32. Manuel A. Espinoza & Andrea Manca & Karl Claxton & Mark J. Sculpher, 2014. "The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis," Medical Decision Making, , vol. 34(8), pages 951-964, November.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.